Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Match Group Inc (MTCH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Match Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.72 (market cap $4.49B), while Match Group Inc trades at $38.05 (market cap $9.14B). The key difference: Match Group Inc is far larger — about 2× ACADIA Pharmaceuticals Inc.'s market cap, and Match Group Inc pays a 2.04% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MTCH | |
|---|---|---|
Market Cap | $4.49B | $9.14B |
Sector | Health | Media |
52-Week High | $28.06 | $39.18 |
52-Week Low | $20.06 | $28.90 |
Enterprise Value | $3.69B | $12.09B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
MTCH trades at $39.18, up 3.38% in the last session, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 73.8% gross margin and 18.83% net income margin, supported by positive cash flow trends. Recent news highlights a turnaround narrative, with Tinder stabilizing and Hinge driving growth.
Outlook is positive with a consensus price target of $41.63, implying 6.3% upside. Risks include high debt levels and user decline concerns. Analysts are bullish (53% buy ratings), but investors should monitor execution on growth initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
